Nectar Lifesciences Secures Ukrainian GMP Certification for Unit VI Amid Planned Slump Sale Aug 11, 2025
Nectar Lifesciences has received GMP certification from Ukraine's SMDC for its Unit VI facility, valid until April 18, 2026. The certification covers pharmaceutical products for sale in Ukraine or export, adhering to PIC/S, EU, and WHO standards. This achievement comes as the company plans a slump sale of the certified facility, which shareholders have already approved. The Unit VI facility is located in Himachal Pradesh, India. Separately, the company's Board will meet on August 14, 2025, to review Q2 2025 financial results.
Nectar Lifesciences Holds EGM: Key Resolutions on Director Appointment and Business Transfer Aug 04, 2025
Nectar Lifesciences to Divest Key Businesses for ₹1,290 Crore Jul 08, 2025
Nectar Lifesciences Reports Q4 Revenue Decline and Significant Loss Jul 08, 2025
More news about Nectar Lifesciences
30Apr 25
Nectar Lifesciences Secures 2-Year GMP Certification from Brazil's ANVISA for Key APIs
Nectar Lifesciences Limited's Unit II in Punjab has received a two-year Good Manufacturing Practice (GMP) certification from Brazil's ANVISA for two Active Pharmaceutical Ingredients: Ceftazidime pentahydrate and Ceftriaxone disodium hemiheptahydrate. The certification, valid from April 28, 2025, covers chemical synthesis and sterilization processes, validating the company's manufacturing standards and potentially opening new opportunities in the Brazilian market.
10Mar 25
Nectar Lifesciences' API Facility Faces Critical Observations in Joint European Inspection
Nectar Lifesciences' API manufacturing facility in Punjab, India, received seven observations, including four critical ones, during a joint inspection by EDQM and AEMPS. The company is preparing a CAPA report and will undergo a re-inspection for EuGMP approval. CEO Amit Chadah reaffirmed the company's commitment to quality and compliance standards.